{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:28:55Z","timestamp":1757618935646,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2018,1,30]]},"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1136\/ejhpharm-2017-001378","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T20:50:23Z","timestamp":1518641423000},"page":"299-301","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the use, effectiveness and safety of tyrosine kinase inhibitors in chronic myelogenous leukaemia in a general university hospital"],"prefix":"10.1136","volume":"27","author":[{"given":"Iratxe","family":"Marquinez-Alonso","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Escudero-Vilaplana","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Osorio","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"},{"name":"Hematology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen G","family":"Rodriguez-Gonzalez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Gonz\u00e1lez-Haba","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Sanjurjo-S\u00e1ez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"2025090701583086000_27.5.299.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"2025090701583086000_27.5.299.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"2025090701583086000_27.5.299.3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"2025090701583086000_27.5.299.4","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","article-title":"Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: a systematic review and meta-analysis of eight randomized trials","volume":"16","author":"Yun","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025090701583086000_27.5.299.5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"2025090701583086000_27.5.299.6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0162"},{"key":"2025090701583086000_27.5.299.7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000339696","article-title":"Evaluation of long-term outcomes, cytogenetic and molecular responses with imatinib mesylate in early and late chronic-phase chronic myeloid leukemia: a report from a single institute","volume":"128","author":"Bendit","year":"2012","journal-title":"Acta Haematol"},{"key":"2025090701583086000_27.5.299.8","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0088-6"},{"key":"2025090701583086000_27.5.299.9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n","year":"2016","journal-title":"Ann Intern Med"},{"key":"2025090701583086000_27.5.299.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00217-2017"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2017-001378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:58:37Z","timestamp":1757235517000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2017-001378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,8,24]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/ejhpharm-2017-001378"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2017-001378","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2018,2,14]]}}}